PTPN11 and cancer: This key function of SHP2 is also reflected by its frequent dysregulation in cancer, either resulting from overexpression of its activators such as docking/adapter proteins of the GAB and FRS families [65] or from the amplification or gain-of-function mutations of PTPN11 itself [82].